Skip to main content

Drug Profiles/Updates

Drug Profiles/Updates, Cholangiocarcinoma

Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

Loretta Fala, Medical Writer

Loretta Fala, Medical Writer

Drug Profiles/Updates, FDA Oncology Update

December 19, 2019 - FDA News & Updates

Hepatocellular Carcinoma, Lymphoma, Drug Profiles/Updates, FDA Oncology Update

November 18, 2019 — Oncology News & Updates

FDA Updates, Gastrointestinal Cancers, Drug Profiles/Updates

Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Prostate Cancer, Drug Profiles/Updates

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

Loretta Fala, Medical Writer

FDA Updates, Leukemia, Drug Profiles/Updates

Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

Breast Cancer, FDA Updates, Drug Profiles/Updates

Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Drug Profiles/Updates

Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Drug Profiles/Updates

Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia

Lisa A. Raedler, PhD, RPh, Medical Writer

Leukemia, Drug Profiles/Updates, FDA Oncology Update

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation

1
2
3
4

Page 1 of 4
Results 1 - 10 of 40